Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 289

1.

Efficacy of treatments for patients with obsessive-compulsive disorder: a systematic review.

Choi YJ.

J Am Acad Nurse Pract. 2009 Apr;21(4):207-13. doi: 10.1111/j.1745-7599.2009.00408.x. Review.

PMID:
19366379
2.

[Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature].

Etain B, Bonnet-Perrin E.

Encephale. 2001 May-Jun;27(3):280-9. Review. French.

PMID:
11488259
3.

Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.

Piccinelli M, Pini S, Bellantuono C, Wilkinson G.

Br J Psychiatry. 1995 Apr;166(4):424-43.

PMID:
7795913
4.

Pharmacologic therapy of obsessive compulsive disorder.

DeVeaugh-Geiss J.

Adv Pharmacol. 1994;30:35-52. Review.

PMID:
7833296
5.

The medical treatment of obsessive-compulsive disorder and anxiety.

Bandelow B.

CNS Spectr. 2008 Sep;13(9 Suppl 14):37-46. Review.

PMID:
18849910
6.

Do antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms? A systematic review.

Sareen J, Kirshner A, Lander M, Kjernisted KD, Eleff MK, Reiss JP.

J Affect Disord. 2004 Oct 15;82(2):167-74. Review.

PMID:
15488245
7.

Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.

Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR.

J Clin Psychiatry. 2005 Jun;66(6):736-43.

PMID:
15960567
8.

Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.

Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, Falkai P, Kapur S, Leucht S, Licht R, Naber D, O'Keane V, Papakostas G, Vieta E, Zohar J.

Eur Neuropsychopharmacol. 2009 Jul;19(7):520-32. doi: 10.1016/j.euroneuro.2009.04.003. Epub 2009 May 2.

PMID:
19411165
9.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
10.

Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases.

McDougle CJ, Fleischmann RL, Epperson CN, Wasylink S, Leckman JF, Price LH.

J Clin Psychiatry. 1995 Nov;56(11):526-8.

PMID:
7592506
11.

Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.

Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L.

Eur Neuropsychopharmacol. 2005 Jan;15(1):69-74.

PMID:
15572275
12.

Fluvoxamine: new indication. No progress in obsessive-compulsive disorder.

[No authors listed]

Prescrire Int. 2004 Oct;13(73):163-5.

PMID:
15499694
13.

Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.

Sevincok L, Topuz A.

J Clin Psychopharmacol. 2003 Oct;23(5):448-50.

PMID:
14520120
14.

Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study.

Koponen H, Lepola U, Leinonen E, Jokinen R, Penttinen J, Turtonen J.

Acta Psychiatr Scand. 1997 Nov;96(5):343-6.

PMID:
9395151
15.

Issues in the pharmacological treatment of obsessive-compulsive disorder.

Math SB, Janardhan Reddy YC.

Int J Clin Pract. 2007 Jul;61(7):1188-97. Epub 2007 May 18. Review.

PMID:
17511795
16.

SSRIs in the treatment of obsessive-compulsive disorder.

Cartwright C, Hollander E.

Depress Anxiety. 1998;8 Suppl 1:105-13. Review.

PMID:
9809222
17.

Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder.

Fineberg NA, Pampaloni I, Pallanti S, Ipser J, Stein DJ.

Int Clin Psychopharmacol. 2007 Nov;22(6):313-22. Review.

PMID:
17917549
18.

Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.

Tundo A, Salvati L, Busto G, Di Spigno D, Falcini R.

J Clin Psychiatry. 2007 Oct;68(10):1552-6.

PMID:
17960971
19.

WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults.

Greist JH, Bandelow B, Hollander E, Marazziti D, Montgomery SA, Nutt DJ, Okasha A, Swinson RP, Zohar J; World Council of Anxiety.

CNS Spectr. 2003 Aug;8(8 Suppl 1):7-16. Review.

PMID:
14767394
20.

Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine.

Mundo E, Rouillon F, Figuera ML, Stigler M.

Hum Psychopharmacol. 2001 Aug;16(6):461-468.

PMID:
12404554

Supplemental Content

Support Center